Kaspofungin Lorien (Caspofungin)

Caspofungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for building β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. By preventing cell‑wall synthesis, the drug weakens the fungus, leading to cell lysis and death while sparing human cells that lack this pathway.

The dosing regimen for Kaspofungin Lorien is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow the approved prescribing information and adjust as needed for individual patients.

Safety data for caspofungin in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Kaspofungin Lorien belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins are often preferred for invasive Candida infections due to their fungicidal activity and lower drug‑interaction potential, while azoles may be used for less severe infections or when oral therapy is required.

Kaspofungin Lorien should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Proper cold‑chain storage helps maintain drug stability and potency.

Kaspofungin Lorien is given by intravenous infusion. The infusion is typically administered over one hour, following a loading dose on the first day and subsequent maintenance doses as prescribed. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious risks include hepatotoxicity (significant liver enzyme elevation), severe hypersensitivity reactions such as anaphylaxis, infusion‑related hypotension or respiratory distress, and rare cases of renal dysfunction. Patients should be monitored closely for any signs of these adverse events, and treatment should be stopped if they occur.

Kaspofungin Lorien is contraindicated in patients with known hypersensitivity to caspofungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled liver disease, or those receiving strong CYP3A4 inducers that could markedly reduce drug exposure.